HUTCHMED (China) Limited (HMDCF)
HUTCHMED (China) Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Hong Kong, HK. The stock last traded at $2.16, up 0.00% on the session, giving a market capitalisation of $1.88B. On trailing twelve-month figures it carries a trailing P/E of 4.58, a net margin of 83.3%. Its beta of 0.43 implies it has historically moved less than the broad market.
HUTCHMED (China) Ltd. operates as a holding company, specializing in the research, development, manufacturing, and sales of both pharmaceutical products and health-focused consumer goods. The company's operations are divided into two main segments: Oncology/Immunology and Other Ventures. The Oncology/Immunology division is dedicated to the discovery, development, and commercialization of targeted therapies and immunotherapies aimed at treating cancer and immunological diseases. In contrast, the Other Ventures segment handles the company's other commercial activities, which include the marketing, production, and distribution of prescription medications and general healthcare products. Established on December 18, 2000, the company maintains its headquarters in Hong Kong.
HUTCHMED (China) Limited is most often compared with the following Healthcare names: